Brief: Aravive Announces FDA Orphan Drug Designation Granted To Batiraxcept For The Treatment Of Pancreatic Cancer

Aravive

28/02/2023 22:21

Feb 28 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO
BATIRAXCEPT FOR THE TREATMENT OF PANCREATIC CANCER
    * ARAVIVE INC - DOSE ESCALATION PORTION OF ONGOING PHASE
1B/2
PANCREATIC ADENOCARCINOMA TRIAL INITIATED, WITH PRELIMINARY
RESULTS EXPECTED IN 2H 2023

Source text for Eikon:  ID:nGNX7l7NBr 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))